Not applicableApproved For MarketingNCT03259633
What this trial is testing
An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1
Who this might be right for
NF type1 With Inoperable Plexiform Neurofibromas
AstraZeneca